Table 3 Comparison of off-treatment response rates between the switch to PegIFN alfa-2b therapy and NA monotherapy.

From: Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs

Outcome

Week 84

Week 108

PegIFN alfa-2b

NAs

P value

PegIFN alfa-2b

NAs

P value

ALT (U/ml)

30.36 (22.75,33.0)

22.87 (16.50,29.0)

0.004

33.40 (18.75,32.0)

29.43 (16.25,29.0)

0.139

HBsAg (log IU/ml)

10.90 (0.05,670.2)

694.3 (331.5,1140.5)

0.000

9.77 (0.05,723.35)

685.3 (328.2,1037.3)

0.000

HBsAg lossn (%)

13 (30.2%)

0 (0%)

0.000

14 (32.6%)

0 (0%)

0.000

HBsAg seroconversion n (%)

13 (30.2%)

0 (0%)

0.000

11 (25.6%)

0 (0%)

0.000

HBeAg loss n (%)

34 (79.1%)

17 (37.8%)

0.000

39 (90.7%)

17 (37.8%)

0.000

HBeAg seroconversion n (%)

25 (58.1%)

7 (15.6%)

0.000

28 (65.1%)

10 (22.2%)

0.000

  1. HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; NAs, nucleos(t)ide analogues; ALT, alanineaminotransferase.
Back to article page